NAD+ Trials, Legal Status, and Where to Buy It for Research (2026)

The assay compartment changes the answer

Only two human studies of directly administered NAD+ have published results, and between them they show why the assay compartment is not a technicality. Matching a report to the material that produced it is the same habit the guide to verifying a certificate against its lot applies at the bench.

The 2019 pilot gave 750 mg of NAD+ by IV infusion over six hours, at 3 micromoles per minute, to eight of eleven participants, with three on saline. For the first two hours nothing moved: no rise in the plasma or urinary NAD-related analytes being followed. By the end of the infusion, plasma NAD+, nicotinamide, methyl-nicotinamide and ADP-ribose all sat around 400 percent above baseline. It was a metabolite study, not a disease-outcome study, and eight participants on the infusion is far too few for its clean adverse-event record to say anything general about safety.

RENEWAL-NAD+ went oral: 2,000 mg of a formulation described as 50 percent NAD+ by mass, daily for five days, in healthy adults, with 50 participants in the primary analysis. At day 6 whole-blood intracellular NAD was 53 percent higher than placebo. Plasma NAD did not rise at all.

That pairing is the useful part. One study found the signal in plasma; the other found it inside cells and nowhere in plasma. Those are different compartments, not different words for the same thing, and the two results would look contradictory to anyone who read only the compound name. A finding here travels with four things attached: the analyte, the compartment, the collection time, and the route and formulation that produced it.

NAD+, NR, NMN and NADH need separate evidence lines

The title of a study is not its intervention. NADream is registered as "Effects of Nicotinamide Adenine Dinucleotide Supplementation" and administers nicotinamide riboside at 2,000 mg daily. NCT03482167, registered as "NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults", administers Niagen, which is NR, at 500 mg twice daily. Both are legitimate precursor studies. Neither one is evidence about administered NAD+, and the precursor literature is considerably larger than the direct one, so the substitution flatters the direct record every time it happens.

The same slippage shows up in identifiers. UNII 8295030YNC gets attached to NAD+ regularly, and the FDA substance record files it as disodium nicotinamide adenine dinucleotide reduced, CAS 606-68-8. That is NADH, the reduced form, not oxidized NAD+. One catalogue name can sit over several distinct chemical entities, which is exactly the situation the guide to reading purity claims and batch documents is written for. Curo's quality and testing standard sets out what each analytical method reports.

The human record is strongest as a measurement map

Read the whole set as a measurement map and it becomes navigable. Intervention first, then biospecimen, analyte, collection time and stated endpoint. Two results only belong side by side once those five line up.

It is also worth remembering what a registry entry is. It records a design, an enrolment figure and a status. A published paper adds findings. A completed status on its own supplies no number, and a biomarker moving is not a disease outcome.

The conclusion is narrow and still useful: form, compartment and timing change the observed NAD profile enough that a comparison which drops them is not really a comparison. The same discipline pays off elsewhere in the longevity literature, and the Epithalon research record shows what happens when you apply it to a compound whose reputation rests on cell-culture work.

Compounding records are separate status lines

Three separate federal records describe where NAD sits, and they answer different questions.

The current text of 21 CFR 216.23 lists six bulk drug substances usable under the 503A pathway. NAD is not one of them. Working backwards, FDA's 2019 proposed rule explains why: the agency evaluated NAD for fatigue in multiple sclerosis, found insufficient clinical data for that use, and proposed not to include it. The same document records that the Pharmacy Compounding Advisory Committee discussed NAD on May 8, 2017.

On the outsourcing-facility side, FDA's March 21, 2025 category document places beta-nicotinamide adenine dinucleotide in Category 1, which the document defines as bulk drug substances under evaluation. Under evaluation is not approval.

One more thing is worth stating because the assumption travels: NAD was not on the July 2026 compounding committee agenda. The Federal Register notice for that meeting, docket FDA-2025-N-6895, scheduled seven peptides and NAD was not among them.

Is NAD+ legal to buy?

In the United States, NAD+ is legal to purchase as a research chemical for laboratory use. It is not a controlled substance and does not appear on any DEA schedule as of August 2026. What it is not: an approved drug, an approved injectable product, or a compound cleared for human or veterinary use in any form.

Three boundaries define the current picture:

1. Research sale is lawful; human-use marketing is not. FDA has repeatedly cited sellers of research compounds whose sites promote human use, and federal courts treat that line seriously. The owner of one vendor, Paradigm Peptides, was sentenced to 70 months in federal prison in July 2026 for selling unapproved and adulterated drugs. The offense was not stocking research material. It was selling it for human consumption while faking the paperwork.
2. No lawful compounded form exists. NAD is absent from the 503A list at 21 CFR 216.23, and FDA files it as Category 1, under evaluation, on the outsourcing-facility side. Under evaluation is a status, not a clearance.
3. The chemical identity has to be pinned down. Because NAD+, NADH, NR and NMN all travel under NAD-adjacent labels, the legal question and the documentation question collapse into one: what exactly is in the vial, and what lot record proves it.

None of this changes how a supplier like Curo operates. NAD+ is sold strictly for laboratory research, not for human or animal use. Curo's research use only policy covers what that means in practice.

Where to buy NAD+ for laboratory research

Researchers looking for where to buy NAD+ face a supplier market that changed sharply in 2025 and 2026. Peptide Sciences closed in March 2026, Amino Asylum went offline after a reported federal raid in June 2025, and Paradigm Peptides ended in a criminal sentencing. Several sites now trade on those dead brand names, so the first check is not price. It is whether the company behind the storefront actually exists. Our guide to the best peptide companies in 2026 covers the current field vendor by vendor.

Five checks separate a documented NAD+ source from an anonymous one:

1. A lot-specific COA, published before purchase. The certificate should match the exact lot on the vial, not a generic product-page badge. Several NAD+ sellers will send a certificate only after an email request, which means the documentation cannot be read before the money moves. The help center shows how to verify a certificate against your lot.
2. A named, independent laboratory. A COA is only as good as the lab that issued it. Court records in the Paradigm case showed the defendants admitted faking certificates outright, which is the failure mode this check exists to catch.
3. Identity and purity by more than one method. For NAD+ this matters more than for most catalogue items, because HPLC purity alone will not separate the oxidized form from NADH, NMN or ADP-ribose degradation products in a reader's mind. Look for mass-spectrometry identity confirmation and endotoxin results alongside the HPLC number.
4. An identifiable company. A legal entity, a real contact route, and consistent policies. A brand name alone is not an identity, and the clone sites trading on dead vendors prove it.
5. Payment with recourse. Card payment carries buyer protection. Venmo, Zelle, and crypto-only checkouts remove it.

Curo stocks NAD+ in 500mg and 1000mg vials in the research catalog. Every lot is tested by an independent laboratory for identity, purity and endotoxin, the full testing standard is documented, and every certificate is publicly readable without an account. Orders are fulfilled from the United States, and payment options include card, crypto, Zelle, and Cash App.

Where to buy NAD+ injection material

Searches for NAD+ injection usually point back to the registered studies, which used sterile solutions prepared under a protocol. That is a clinical supply chain, and it is not what a research catalogue sells. What is available for purchase is lyophilized research-grade NAD+ in a sealed vial, supplied for laboratory work and nothing else. Curo lists it for research use only, and the practical question for a buyer is identical to the one above: which lot is in the vial, and is that lot's certificate readable before checkout.

How much does NAD+ cost?

As of August 2026, research-grade NAD+ runs about $80 to $120 for a 500mg vial and about $105 to $180 for a 1000mg vial from US suppliers that publish lot-matched, independently issued COAs. Cheaper vials exist, some near $40, but they cluster among suppliers with no published lot documentation or with certificates released only by email request after purchase, and an unverified lot is unusable as research material at any price. Vial size drives the real comparison, so normalize per milligram: the documented 500mg vials work out to roughly $0.16 to $0.24 per milligram. Curo's NAD+ 1000mg is $149, which is about $0.15 per milligram, under the whole documented 500mg band, and the 500mg vial is $119 for labs that need the smaller fill. Compare the documentation attached to the current batch first, then the price. The pre-purchase checklist walks the full sequence.

What an NAD+ certificate of analysis should show

NAD+ is produced by many suppliers and sold under several closely related names, so material identity is something a lab confirms rather than assumes. A certificate worth relying on shows:

• The exact lot number that appears on the vial.
• The issuing laboratory's name and report identifier.
• HPLC purity with the chromatogram, not a bare percentage.
• Mass-spectrometry identity confirmation against the expected 663.43 g/mol for oxidized NAD+, which is what separates it on paper from NADH at 665.4 g/mol and from NMN.
• An endotoxin result, since a pure compound can still carry bacterial contamination from production.
• A way to verify the document independently, through a public lookup or the lab itself. Curo's COA database is open for exactly this reason.

A well-tested lyophilized vial can still be degraded by poor handling after receipt. See storing research peptides and bacteriostatic water for the storage side.

For a broader framework on separating documentation from marketing when comparing suppliers, see how to evaluate research peptide companies.

Further reading

The same reading discipline pays off across the longevity literature. Epithalon's research record shows what a reputation built largely on cell-culture work looks like when the compartments and models are pulled apart.

For the documentation side in isolation, purity claims and COA batch documentation covers how to read a certificate that is technically accurate and still tells you very little.

Frequently asked questions

What does "NAD increased" leave out?

It leaves out the analyte, sample compartment, collection time, administration route and formulation. Those details define what was actually measured.

Can the registered study amounts be used as administration guidance?

No. Each amount belongs to a named protocol with its own route, schedule, formulation, comparator and measurement plan.

Which NAD+ administration route has the strongest human evidence?

The current studies are too different in formulation, schedule, comparator, assay and endpoint to rank IV, IM, subcutaneous, oral, IV-push or iontophoresis delivery on one scale.

Is NAD+ legal to buy in the US?

Yes, as a research chemical for laboratory use. NAD+ is not a controlled substance as of August 2026. It is not approved for human use, and no lawful compounded form exists: NAD is absent from the 503A bulk substances list and sits in FDA Category 1, under evaluation, for outsourcing facilities.

Where can a researcher buy NAD+?

From suppliers that publish lot-specific, independently issued COAs and operate as identifiable companies. Several well-known vendors closed or faced federal action in 2025 and 2026, and clone sites now trade on their names, so verify the company before the price. Curo lists NAD+ for laboratory research with every lot's certificate published openly.

How much does NAD+ cost?

Suppliers that publish lot-matched third-party COAs typically charge $80 to $120 for a 500mg vial and $105 to $180 for a 1000mg vial as of August 2026. Curo's 500mg vial is $119 and the 1000mg vial is $149, with the lot's certificate published before purchase. Vials well under those ranges usually come without verifiable lot documentation.

What should I check when a label says NAD+?

Check the exact chemical form first, then match it to the lot-specific identity and purity documentation. NAD+, NADH, NR and NMN are distinct entities, and a broad catalogue name is not precise enough for evidence matching.

What should a certificate of analysis for NAD+ show?

Lot-specific identity and purity data from chromatographic and mass-spectrometry methods, plus endotoxin results, tied to the exact lot number on the vial and verifiable through a public lookup.